Multiple Sclerosis CD19+ B Cells
Multiple Sclerosis CD19+ B Cells are purified from peripheral blood of IRB-consented donors with confirmed MS and cryopreserved in CryoStor CS10. B cells drive relapsing MS largely through antigen presentation and pro-inflammatory cytokine output rather than a single pathogenic autoantibody, which is why anti-CD20 depletion works so quickly. Suited to B-cell phenotyping, BCR repertoire sequencing, BTK inhibitor pharmacology and EBV studies, with subtype, EDSS and treatment stratification.
Multiple Sclerosis CD19+ B Cells for Neuroimmunology and Autoimmune Research
Multiple Sclerosis CD19+ B Cells are purified from the peripheral blood of IRB-consented adult donors with a clinically confirmed diagnosis of multiple sclerosis (MS), processed within 24 hours of collection and cryopreserved in CryoStor CS10 media. MS is an autoimmune, inflammatory demyelinating disease of the central nervous system, and B cells are now understood to be a central driver of relapsing disease rather than a bystander population.
Why CD19+ B Cells in Multiple Sclerosis
- The case for B cells in MS was established therapeutically: B-cell depleting anti-CD20 antibodies markedly reduce relapse rate and new lesion formation, and they do so within weeks, faster than antibody titres could plausibly fall. That argues for antibody-independent B-cell functions as the operative mechanism.
- Those functions include antigen presentation to CD4 T cells and secretion of pro-inflammatory cytokines such as GM-CSF, IL-6, TNF and lymphotoxin, alongside impaired regulatory (IL-10-producing) B-cell activity. Isolated CD19+ B cells let these outputs be measured directly rather than inferred from bulk PBMC.
- Unlike NMOSD or MOGAD, MS has no single established pathogenic autoantibody. What is well documented is intrathecal immunoglobulin synthesis, seen as cerebrospinal fluid oligoclonal bands and an elevated IgG index, together with meningeal B-cell aggregates in progressive disease. Peripheral CD19+ B cells provide the accessible compartment for repertoire and clonality studies that connect to that intrathecal activity.
- Memory B cells appear to be the key pathogenic reservoir, and CD19 selection captures a broader B-lineage range than CD20 selection, including plasmablasts that CD20-directed therapies largely spare, which matters when studying residual disease activity under treatment.
- Epstein-Barr virus infection has a strong and consistent epidemiological association with MS risk, and B cells are the natural host cell for EBV latency, making isolated MS B cells the relevant substrate for research into that relationship.
- Cryopreserved, purified B cells support BCR repertoire sequencing, in vitro activation and differentiation, antigen-presentation co-culture assays and depletion or signalling-inhibitor pharmacology in patient-derived cells.
Donor Stratification Available
- MS subtype: relapsing-remitting, secondary progressive, or primary progressive where documented
- Disability and disease duration, including EDSS where documented
- Clinical state: recent relapse versus clinical remission
- Treatment status: treatment-naive, or on interferon beta, glatiramer acetate, dimethyl fumarate, S1P modulator, natalizumab, anti-CD20 therapy (note that B-cell yields are reduced or absent in recently depleted donors), or cladribine
- CSF findings where documented, including oligoclonal band status and IgG index; MRI lesion burden where documented
- Matched healthy control CD19+ B cells available, and B cells from other autoimmune donors for comparison
Product Features
- Research Use Only (RUO), CD19+ B cells
- Isolated from multiple sclerosis donors with confirmed clinical diagnosis
- High purity and viability; values reported per lot
- Cryopreserved using CryoStor CS10 media
- Processed within 24 hours of collection
- Standard and custom aliquot sizes; matched autologous PBMC and plasma available on request
- IRB-approved protocols and HIPAA-compliant handling
De-identified Donor Data
- Confirmed diagnosis of multiple sclerosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and clinical history available
- MS subtype and disease-specific detail available on request
Applications
- B-cell immunophenotyping across naive, memory, double-negative and plasmablast compartments
- B-cell cytokine output profiling, including GM-CSF, IL-6 and IL-10
- Antigen presentation and B-cell/T-cell co-culture assays
- BCR repertoire sequencing and clonality analysis
- B-cell receptor signalling and BTK inhibitor pharmacology
- Anti-CD20 and B-cell depletion mechanism-of-action research
- EBV latency and virus-host interaction studies in patient B cells
- Biomarker discovery and therapeutic target validation in neuroimmunology
Other Multiple Sclerosis Specimen Types
- Multiple Sclerosis PBMC
- Multiple Sclerosis Leukopak
- Multiple Sclerosis Serum
- Multiple Sclerosis Plasma
- Multiple Sclerosis Whole Blood
- Multiple Sclerosis Cerebrospinal Fluid
- Multiple Sclerosis CD4+ T Cells
- Multiple Sclerosis CD8+ T Cells
Compliance and Quality Assurance
- IRB-approved collections with 21 CFR Part 11-compliant e-consent
- Standardized processing and cryopreservation protocols
- HIPAA-compliant donor data protection
Ordering & Customization
Multiple Sclerosis CD19+ B Cells are available in standard or custom aliquot sizes. For pricing, current availability, or a quote on a stratified donor cohort, contact learnmore@sanguinebio.com; email us as well for international shipping, documentation or regulatory support. To browse other disease states and the source material these cells are isolated from, visit our human CD19+ B cells and human PBMC pages.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
CD19+ B Cells
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
1 Answer
All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more on our PRO surveys and questionnaires page.
Ask a Question
Need a custom CD19+ B Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.